Francois Nader

MD, MBA; Chairman, Acceleron Pharma, Benevolent AI, Talaris/Board Member, Moderna/Senior Advisor, Blackstone Life Sciences

Francois Nader, MD, is a leading value builder in the biopharma industry. Dr. Nader serves as chairman of BenevolentAI (BAI), Talaris Therapeutics (TALS) and Neurvati Neurosciences, as board director of Moderna (MRNA) and RING Therapeutics and as senior advisor of Blackstone Life Sciences. Previously, Dr. Nader was Chief Executive Officer of NPS Pharma. During his tenure, Dr. Nader transformed NPS Pharma into a leading global biotechnology company focused on delivering innovative therapies to patients with rare diseases. Dr. Nader won the Ernst and Young National Life Science Entrepreneur of the Year® award in 2013. Before NPS, Dr. Nader was a venture partner at Care Capital. Prior, he served on the North America Leadership Team of Aventis and its predecessor companies holding several executive positions including senior vice-president, integrated healthcare markets and North America medical and regulatory affairs. Previously, he led the global commercial operations at the Pasteur Vaccins’ division of Rhone-Poulenc. Dr. Nader is past chairman of BioNJ, Acceleron Pharma (XLRN) acquired by Merck, Prevail Therapeutics (PRVL) acquired by Lilly and served as board director of Alexion (ALXN) acquired by Astra Zeneca, Clementia Pharmaceuticals (CMTA) acquired by IPSEN, Advanced Accelerator Applications (AAAP) acquired by Novartis, Baxalta (BXLT) acquired by Shire, and Noven (NOVN) acquired by Hisamitsu. Dr. Nader earned his French Doctorate in Medicine from St. Joseph University (Lebanon) and his Physician Executive MBA from the University of Tennessee.